PHVS · Pharvaris N.V.
$36.39
+0.12 (+0.33%)
At close · Aug 20
Market Cap
$2.55B
Shares
70.20M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$36.39
Open$36.13
Day$35.45–36.82
52W close$20.96–36.46
Avg vol 30d485K
Short int1.2M · 1.7% float · 3.8d
Short vol20%
DataFeb 2021–Aug 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+26%
above
Price vs 50-day avg
+7%
above
RSI (14)
59
neutral
MACD trend
Positive
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+9%
trailing
6-month return
+28%
trailing
YTD return
+31%
this year
Relative strength
+17%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $34 › 200d $29 — 50d above 200d
Institutional flow
Accumulating
+12% holders QoQ · +23 funds added
Insider flow
Distributing
Net -$82.4K over 90 days · 100% sells
Short interest
Rising
1.70% of float · ▲ +5.0% MoM · 3.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
124 holders — near 3-yr high, broad support
Squeeze score
59
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
56%
annualized · 1-yr
Max drawdown
−19%
past year
ATR
4.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+26%
Bullish
Price vs 50-day avg
+7%
Bullish
RSI (14)
59
Neutral
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $34 › 200d $29 — 50d above 200d
Institutional flow
Accumulating
+12% holders QoQ · +23 funds added
Insider flow
Distributing
Net -$82.4K over 90 days · 100% sells
Short interest
Rising
1.70% of float · ▲ +5.0% MoM · 3.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
124 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $21
Now $36 · 100%
Range high $36
vs 200-day avg +26%
vs 50-day avg +7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PHVS
this stock
Pharvaris N.V.
|
$2.55B | +31.1% | — | — | 1.7% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PHVS | +6.9% | +9.4% | +28.2% | +11.6% | +31.1% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +8.9% | +6.1% | +17.0% | +9.5% | +19.3% |
Key facts
CIK
1830487
CUSIP
N69605108
13F (30d)
122 filings
121 filers
Visit website
Investor relations